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Myopathies are a clinically and etiologically heterogeneous group of disorders that can range from limb girdle muscular dystrophy
(LGMD) to syndromic forms with associated features including intellectual disability. Here, we report the identification of mutations
in transport protein particle complex 11 (TRAPPC11) in three individuals of a consanguineous Syrian family presenting with LGMD
and in five individuals of Hutterite descent presenting with myopathy, infantile hyperkinetic movements, ataxia, and intellectual
disability. By using a combination of whole-exome or genome sequencing with homozygosity mapping, we identified the homozygous
c.2938G>A (p.Gly980Arg) missensemutation within the gryzun domain of TRAPPC11 in the Syrian LGMD family and the homozygous
c.1287þ5G>A splice-site mutation resulting in a 58 amino acid in-frame deletion (p.Ala372_Ser429del) in the foie gras domain of
TRAPPC11 in the Hutterite families. TRAPPC11 encodes a component of the multiprotein TRAPP complex involved in membrane
trafficking. We demonstrate that both mutations impair the binding ability of TRAPPC11 to other TRAPP complex components and
disrupt the Golgi apparatus architecture. Marker trafficking experiments for the p.Ala372_Ser429del deletion indicated normal ER-to-
Golgi trafficking but dramatically delayed exit from the Golgi to the cell surface. Moreover, we observed alterations of the lysosomal
membrane glycoproteins lysosome-associated membrane protein 1 (LAMP1) and LAMP2 as a consequence of TRAPPC11 dysfunction
supporting a defect in the transport of secretory proteins as the underlying pathomechanism.Limb girdle muscular dystrophies (LGMDs) are a heteroge-
neous group of genetic myopathies leading primarily to
proximal muscle weakness, with relative sparing of heart
and bulbar muscles, except for some subtypes.1,2 So far
mutations at over 50 loci with either autosomal-dominant
(LGMD1) or autosomal-recessive inheritance (LGMD2)
have been described.3 The major forms of LGMD result
from mutations in genes encoding constituents of
the sarcolemmal dystrophin complex, e.g., laminin
(LGMD1B), sarcoglycan (LGMD2C-F), and dysferlin
(LGMD2B). Other forms, however, result from mutations
in genes affecting muscle function via different pathome-
chanisms involving membrane trafficking,4 muscle
remodeling,5 and posttranslational modification of sarco-
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The Amprogression vary considerably between LGMD subtypes,
ranging from early childhood myopathy to adult onset
with long-time preserved ambulation. The spectrum of
dystroglycanopathies even ranges from mild LGMD to se-
vere congenital muscular dystrophy with brain and eye
involvement and severe intellectual disability (ID).6 ID is
defined as an intelligence quotient <70 and significant
limitations in two or more adaptive skills identified in
childhood7 and is found in 1%–3% of the general popula-
tion.8 ID is etiologically heterogeneous with genetic and
nongenetic causes and can be found as the sole clinical
feature in nonsyndromic ID or as part of a syndrome
with other clinical manifestations. Disruption of a number
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Figure 1. Pedigrees and Molecular Char-
acterization of the TRAPPC11 Mutations
(A) Pedigree structure of families 1, 2, and 3.
(B) Representative wild-type (WT) and
mutant electropherograms from family 1.
The c.2938G>A mutation is indicated by
a black arrow.
(C) Representative WT and mutant electro-
pherograms from families 2 and 3 demon-
strating the homozygous c.1287þ5G>A
mutation (indicated by a black arrow) in
relation to the exon 12 and intron 12
boundary.
(D) RT-PCR analysis confirmed the pres-
ence of altered C11 splicing in lympho-
cytes obtained from one carrier parent,
two affected individuals, and two controls.
Numbers 1, 2, 3, and 4 correspond to
different transcripts illustrated in (E).
(E) Schematic representation of these RT-
PCR products after gel isolation and Sanger
sequencing. In control cells, the full-length
transcript (1) predominates over an alterna-
tively splicedminor transcript lacking exon
11 (2). In cells from affected individuals,
the minor transcript lacks only exon 12
(3), whereas the predominant transcript
(4) lacks both exons 11 and 12, resulting
in an in-frame deletion of 58 amino acids
(p.Ala372_Ser429del).
(F) Schematic representation of TRAPPC11
and the location of the foie gras and gryzun
domains. The two mutations identified in
this study are indicated by black arrows.neuronal development and synapse formation, and intra-
cellular signaling, as well as intracellular trafficking.8,9
Here, we report on the clinical, molecular, and cellular
phenotype of an autosomal-recessively inherited disease
spectrum that ranges from LGMD to a syndrome character-
ized by myopathy, ID, hyperkinetic movements, and
ataxia, resulting from altered vesicle trafficking.
The study was conducted on a consanguineous Syrian
family with an uncharacterized form of LGMD (family 1;
Figure 1A) and two families of Hutterite ancestry10,11
(families 2 and 3; Figure 1A) with affected individuals
presenting with a myopathic syndrome associated with
moderate ID, infantile hyperkinetic movements, and
ataxia. All subjects or their legal representatives gave writ-
ten informed consent to the study and the research proto-
cols were approved by the respective institutional review
board. The study was performed in accordance with the182 The American Journal of Human Genetics 93, 181–190, July 11, 2013Declaration of Helsinki protocols.
Fibroblasts were cultivated from a
skin biopsy from individual III-8 of
family 1 and the two siblings (II-6
and II-8) from family 2 following stan-
dard protocols after written informed
consent had been given.
The three affected individuals from
family 1 were born to healthy first-
cousin parents (Figures S1A–S1C).They suffer from a progressive proximal muscle weakness,
with onset by early school age and 9- to 16-fold increased
serum creatine kinase (CK) levels, that led to different
degrees of impaired ambulation. The younger cousins are
ambulatory with moderate limitations due to fatigue and
muscle pain, whereas the eldest cousin (III-3), at age 26,
has severely limited mobility (unable to climb stairs, walks
short distances with much difficulty) reflecting the pro-
gressive nature of the disease. In all affected individuals,
the shoulder girdle muscles are less severely involved
than the hip girdle musculature. Skeletal findings, present
in all affected individuals, include hip dysplasia and scoli-
osis. In addition, individual III-3 presented with a mild
bilateral cataract and individual III-8 showed strabismus
convergens. Except for a slight enlargement of the
right cardiac ventricle in individual III-9, there was no
obvious cardiac or bulbar muscle involvement (Table 1).
Table 1. Clinical Features
Individual
Family 1 Family 2 Family 3
III:8 III:9 III:3 II:2 II:6 II:8 II:2 II:3
TRAPPC11
mutation
c.2938G>A
p.Gly980Arg
c.2938G>A
p.Gly980Arg
c.2938G>A
p.Gly980Arg
c.1287þ5G>A c.1287þ5G>A c.1287þ5G>A c.1287þ5G>A c.1287þ5G>A
Gender female female female male male male female male
Age (years) 20 16 26 25 22 20 20 18
Height (centile) 10th 25–50th 25th <5th 3rd <3rd 50th 5–10th
OFC (centile) 25th 50–75th 10–25th 50th <2nd <<<3rd <3rd <3rd
Muscular
symptoms
prox. weakness,
muscle pain,
muscle cramps
prox. weakness,
muscle pain,
muscle cramps
prox. weakness,
muscle pain
none mild muscle
weakness
none none Hypotonia in
early childhood
Muscle biopsy n/a n/a myopathic
changes
myopathic
changes
myopathic
changes
n/a n/a n/a
CK levels (u/l) ~2,700 1,300–2,800 600–1,600 490–1,215 300–600 700–1,000 1,009 728
DTR UEþ/ LE UEþ/ LEþ UE/ LE UEþ/ LEþ UEþ/ LEþ UEþ/ LEþ UEþ/ LEþ UEþ/ LEþ
Heart not involved enlarged RV not involved not involved not involved not involved not involved not involved
Skeletal
symptoms
hip dysplasia,
scoliosis, no
contractures
hip dysplasia,
mild scoliosis,
no contractures
hip dysplasia,
scoliosis, no
contractures
limb
asymmetry
none none none none
Intellectual
disability
no no mild mild to
moderate
moderate moderate mild, IQ 60
(WISC-III)
mild, IQ 60
(TONI-3)
Development motor delay normal unknown global delay global delay global delay global delay global delay
Seizures none none none none abnormal
EEG
primary
generalized
abnormal
EEG
none
Ataxia none none none truncal truncal truncal truncal truncal
Choreiform
movements
none none none truncal and
limb
truncal and
limb
generalized generalized limb and
facial
Neuroimaging
(MRI)
n/a n/a n/a normal mild cerebral
atrophy
mild cerebral
atrophy
normal normal
Ocular esotropia,
myopia
none bilateral cataract,
myopia
none none none exophoria
anisometropia,
amblyopia
none
CK, creatine kinase; DTR, deep tendon reflexes; EEG, electroencephalogram; ID, intellectual disability; LE, lower extremity; MRI, magnetic resonance imaging; n/a,
not applicable; OFC, occipital frontal circumference; Prox., proximal; RV, right ventricle; TONI-3, Test of Nonverbal Intelligence, Third Edition v3; UE, upper
extremity; u/l, units/liter; WISC, Wechsler Intelligence Scale for Children; þ, normal; , absent.Pulmonary function testing revealed a moderate restrictive
respiratory disorder in individual III-3, while clinical signs
of sleep disordered breathing could not be objectified by
overnight oxymetry and capnography. The younger
cousins do not yet show signs of respiratory involvement.
Individual III-3 displayed mild ID.
We performed whole-exome sequencing on DNA
extracted from blood lymphocytes of individual III-8. After
enrichment of exonic sequences with the SureSelect
Human All Exon 50 Mb kit (Agilent Technologies, Santa
Clara, CA, USA), the exome was sequenced on an Illumina
Genome Analyzer IIx Sequencer (Illumina, San Diego, CA,
USA) with two lanes of a single-end 150 basepair protocol.
Bioinformatic analysis of all exome variants was used to
determine stretches of homozygosity. To refine the homo-
zygous regions, we additionally performed genome-wide
linkage analysis in the three affected individuals and theirThe Amparents by using the Affymetrix GeneChip Human Map-
ping 250K Array (Affymetrix, Santa Clara, CA, USA). Geno-
types were called by the GeneChip DNA Analysis Soft-
ware (GDAS v2.0, Affymetrix) and analyzed as previously
decribed.12–16 Linkage analysis was performed assuming
autosomal-recessive inheritance, full penetrance, consan-
guinity, and a causative variant frequency of 0.0001. A sin-
gle linked homozygous region of 1.03 Mb on chromosome
4q35.1 (defined by SNPs rs6823077 and rs12502711; chr4:
183833940–184866656, hg19; Figures S1D and S1E)
containing nine annotated genes was determined. The
only unannotated variant in the exome data set within
this critical region was the homozygous missense variant
c.2938G>A (p.Gly980Arg; Figure 1B) in TRAPPC11 (Table
S1; RefSeq accession number NM_021942.5). TRAPPC11
codes for a 1,133 amino acid protein containing a so-called
foie gras and a gryzun domain (Figure 1F). The varianterican Journal of Human Genetics 93, 181–190, July 11, 2013 183
affects a highly conserved amino acid residue within the
gryzun domain (Figure 1F; Figure S1F) that is predicted to
affect protein structure by PolyPhen-2. Cosegregation of
the c.2938G>A variant within the family was confirmed
by Sanger sequencing (data not shown). The mutation
was not found in 100 healthy Turkish controls tested either
by restriction enzyme digestion with the enzyme Mval or
direct Sanger sequencing and is not annotated in any
current database of human variation including >12,000
alleles of the Exome Variant Server (Exome Variant Server,
NHLBI GO Exome Sequencing Project [ESP], Seattle, WA).
Furthermore, screening of all coding exons of TRAPPC11
by Sanger sequencing in 32 German single cases of unclas-
sified recessive LGMD did not identify an additional
TRAPPC11mutation. Screening of the exome data of genes
in which recessive mutations are known to cause LGMD
did not identify a pathogenic mutation.
The Hutterites are an endogamous Anabaptist group
that arose during the Protestant Reformation in South
Tyrol and, upon arrival in North America during the
1870s, established three groups, the Dariusleut, Schmiede-
leut, and Lehrerleut that have remained mostly geneti-
cally isolated from one another.17 The Hutterite families
in this study consisted of two affected brothers and their
affected first cousin from the Dariusleut Hutterites of
Alberta (family 2; Figure 1A; Figures S2A and S2B) and
two affected siblings (one male, one female) from
the Schmiedeleut Hutterites of South Dakota (family 3;
Figure 1A; Figures S2C and S2D). An eight-generation
pedigree connects the affected individuals to their most
recent common Hutterite ancestors, a couple born in the
1790s (Figure S3), prior to the founding of the three leuts.
All affected individuals from families 2 and 3 have a his-
tory of early onset developmental delay and as young
adults now have mild to moderate ID. There is no history
of regression, and neuroimaging was unremarkable; in
particular, no abnormalities in the cerebellum or basal
ganglia were observed. As young children, they all had sig-
nificant evidence of a hyperkinetic movement disorder
mainly characterized by choreiform movements of trunk,
limbs, and head although athetoid movements, tremors,
and dystonic posturing were also noted. In addition, all
affected individuals had a truncal ataxia resulting in
further gait instability (Table 1). Metabolic investigations
including plasma, urine, and cerebrospinal fluid failed to
identify any specific anomalies. Mild muscle weakness
with persistently elevated CK levels suggested an associ-
ated myopathy. The two limb girdle muscular dystrophies
known to be present in the Hutterite population,
LGMD2H (MIM 254110; TRIM32, NM_012210.3,
c.1459G>A; p.Asp487Asn)18 and LGMD2I (MIM 607155;
FKRP, NM_024301.4, c.826C>A; p.Leu276Ile)19 were
excluded in all five individuals by Sanger sequencing.
Although the two families were not closely related, a
founder mutation with an autosomal recessive mode
of inheritance was suspected because of the Hutterites’
history of genetic isolation.184 The American Journal of Human Genetics 93, 181–190, July 11, 2Homozygosity mapping in the two affected siblings
from family 2 and two of their unaffected siblings was
performed by using a 10K SNP genotyping microarray
(Affymetrix), and two relevant blocks of homozygosity
on chromosomes 1p31.3 and 4q34.3-q35.1 were identified
(Figure S2E). Haplotype analysis across the two regions
including all three affected individuals from family 2 ruled
out the region on chromosome 1p31.3 (data not shown).
The remaining region on chromosome 4q34.3-q35.1
(flanked by the SNPs rs721684 and rs726466; chr4:
177850523–186546056, hg19) was 8.7 Mb in size and
contained 47 predicted or known genes and 10 predicted
or known noncoding RNAs (Table S2). Whole-exome
sequencing was undertaken on a single affected individual
from family 2 by using the SureSelect Human All Exon v2
kit (Agilent Technologies) and paired-end sequencing
on an Illumina GAII (Illumina) performed commercially
by Perkin Elmer (Branford, CT, USA). Reads were mapped
to the reference sequence and variants were called by
using the CLC genomics workbench (CLCbio, Cambridge,
MA, USA). Within the single region of shared identity
by descent, only three variants were not in dbSNP
with a population frequency of less than 0.02. Only
the c.1287þ5G>A splice-site variant at the donor site
of exon 12 of TRAPPC11 (NM_021942.5; Figure 1C)
was considered to be pathogenic. The variant was pre-
dicted to abolish the exon 12 splice donor site by
in silico analysis by using the Alamut software (Interactive
Software, San Diego, CA).
Family 3 was investigated by whole-genome sequencing
(Complete Genomics, Mountain View, CA, USA) of both
affected siblings and both parents. A total of 2,714 variants
were heterozygous in both parents, homozygous in both
affected siblings, and absent in the homozygous state in
a database of 94 other Hutterite genomes. However, only
eight of these were annotated as altering the protein-
coding sequence or splicing of a gene. With the exception
of TRAPPC11 c.1287þ5G>A, the samemutation identified
in family 2, these remaining variants were common
(minor allele frequency R10%) in the other Hutterite
genomes or in dbSNP. TRAPPC11 is located within a
1.69 Mb homozygous haplotype on chromosome 4q35.1
(chr4: 184562444–186254248, hg19) shared by both
affected siblings in family 3. Segregation studies via Sanger
sequencing of TRAPPC11 c.1287þ5G>A in both family 2
and 3 verified that all five affected individuals were homo-
zygous for the variant, all parents were heterozygous, and
all unaffected siblings carried one or no copies of the
variant (data not shown).
The same c.1287þ5G>A mutation identified in two
separate Hutterite leuts in individuals with similar pheno-
types substantiated the suspicion of a founder mutation
present prior to the leut subdivision. Thus, we screened
for this mutation in a normal control population of
1,827 individuals from all three Hutterite leuts by using a
custom TaqMan genotyping assay (Applied Biosystems,
Foster City, CA, USA) and did not identify any individuals013
who were homozygous for the mutant allele, adding
support for the pathogenicity of this mutation. We
observed carrier frequencies of approximately 7% in both
the Dariusleut and Schmiedeleut. The mutation was not
detected in the Lehrerleut (Table S3). Given the carrier fre-
quencies in the two leuts, we would expect approximately
1 in 750 individuals to be homozygous for this mutation,
suggesting that this mutation might account for some of
the unexplained syndromic forms of ID in the Hutterite
population.
Because the TRAPPC11 c.1287þ5G>Amutation was pre-
dicted to alter splicing of the exon 12 donor site, we deter-
mined the effect on the mature TRAPPC11 transcript by
using RT-PCR followed by sequencing of the resulting frag-
ments. In control lymphocytes, two splice isoforms were
observed: the predominant splice isoform consists of the
full-length transcript, whereas the minor splice isoform
lacks exon 11 and is predicted to result in premature pro-
tein truncation (Figures 1D and 1E). In lymphocytes
from affected individuals, the predominant splice isoform
lacks both exons 11 and 12 resulting in a 58 amino acid
in-frame deletion in the foie gras domain (p.Ala372_
Ser429del), whereas the minor splice isoform lacks only
exon 12 and is predicted to result in a prematurely trun-
cated protein (Figures 1D and 1E). Multiple species align-
ment of TRAPPC11 using Multalin17 demonstrated
numerous amino acids within the deleted segment that
are highly conserved (Figure S2F), suggesting that this
region is important in protein function.
TRAPP (transport protein particle) is a multiprotein com-
plex involved in ER-to-Golgi trafficking.20 It was initially
identified in Saccharomyces cervisiae21 and is conserved
across species.22 The subunit TRAPPC11 (C11) is a TRAPP
component that is important for complex integrity and
anterograde membrane transport from the endoplasmic
reticulum (ER) to the ER-to-Golgi intermediate compart-
ment (ERGIC) in mammals.22 It is ubiquitously expressed
in humans, reflecting its important role in basic cellular
functions. C11 participates in numerous interactions
with other TRAPP complex components, most notably
TRAPPC2 (C2), TRAPPC2L (C2L), TRAPPC6, TRAPPC10,
and TRAPPC12.22 Loss-of-function mutations in the zebra-
fish ortholog of C11 have been found in the foie gras
mutant, characterized by steatohepatitis and eye devel-
opment defects, respectively.23,24 In Drosophila S2 cells,
RNAi knockdown of C11 blocks Golgi exit.25 In HeLa cells,
small interfering RNA (siRNA) knockdown of C11 leads to
impaired binding of other TRAPP components, functional
impairment of the complex, retention of secretory
proteins in the ERGIC, and fragmentation of the Golgi
apparatus.22,25
Immunostaining of the Golgi apparatus with the marker
protein GM130 (BD Biosciences, San Jose, CA, USA) was
performed in primary fibroblasts from individual III-8 of
family 1 and the two siblings from family 2, as well as
on control cells. Punctate Golgi dispersal was observed in
cells from affected individuals similar to that seen afterThe AmTRAPPC11 knockdown in HeLa cells22 (Figures 2A–2E).
Quantitation of the fragmented phenotype indeed shows
a higher percentage of cells with a fragmented Golgi in
cells from affected individuals compared to controls
(Figure 2F). The Golgi phenotype was confirmed by immu-
nostaining for a second Golgi marker mannosidase II
(manII; courtesy of Dr. Kelley Moremon) in family 2
(data not shown). Confocal microscopy of the Golgi in
individual III-8 from family 1 further illustrated the scat-
tered Golgi network (Figure 2G) and three-dimensional
(3D) reconstruction of confocal microscopy images from
family 2 confirmed that the fragmentation is due to fewer
and/or thinner connections between the GM130-positive
structures (Figures 2H and 2I).
Consistent with the punctate Golgi seen upon C11
knockdown, immunoblot analysis demonstrated a quanti-
tative reduction of full-lengthmutant C11 protein in fibro-
blasts from families 1 and 2 (Figures 2J and 2K). In family 2,
there is an accumulation of what might possibly be
TRAPPC11 fragments due to their cross-reactivity with
anti-TRAPPC11. If these fragments are indeed truncated
polypeptides of TRAPPC11, they are incapable of interact-
ing with TRAPPC2 (Figure 2L), suggesting that the insta-
bility of TRAPPC11 in these individuals might either cause
or result from an inability to interact with TRAPP, a distinc-
tion that we cannot presently address. Similarly, although
C11 p.Gly980Arg was unstable in cells derived from
affected individuals, we exploited the stability of this
protein in a yeast system to demonstrate that the protein
loses its ability to interact with several TRAPP proteins
by yeast two-hybrid analysis (Figure S4). An unrelated
substitution in proximity to C11 p.Gly980Arg (C11
p.Trp986_Arg988delinsAlaGluAsp) also showed the same
inability to interact with TRAPP proteins (Figure S4;
Table S4) indicating that this region of C11 might be
important for its interactions and stability.
In order to determine whether cells from affected indi-
viduals also displayed a block in membrane traffic between
the endoplasmic reticulum (ER) and the Golgi, we used
VSV-G-ts045-GFP (VSV-G) as a marker for transport along
the secretory pathway. This commonly used marker
protein misfolds at elevated temperatures (40C) and is
retained in the ER. Upon shifting to lower temperature
(32C) and in the presence of the protein synthesis inhib-
itor cycloheximide, the ER-restricted material exits and is
transported to the Golgi and ultimately to the cell sur-
face.26 The kinetics of this transport is well documented
with appearance of the protein in the Golgi within
minutes of release, where it can reside for up to 40 minutes
before transport to the cell surface.27 We assessed VSV-G
localization in fibroblasts from affected individuals from
family 2 and control fibroblasts, in conjunction with the
Golgi marker manII, at fixed intervals. The trafficking
experiments were performed in cell lines from both
affected individuals from family 2; however, data is shown
only for individual II-8 for simplicity. After incubation at
40C, VSV-G is found exclusively in the ER in both controlerican Journal of Human Genetics 93, 181–190, July 11, 2013 185
Figure 2. TRAPPC11 Mutations Alter Golgi Morphology, Protein Stability and TRAPP Assembly
(A–E) Immunostaining of fibroblasts from affected individuals and controls with GM130 antibody and DAPI show that the affected
individuals have disrupted Golgi morphology compared to healthy controls. Scale bars represent 10 mm.
(F) Quantitation of the Golgi phenotype seen in the cells from (C)–(E). A minimum of 300 cells for each sample were quantitated over
three independent experiments.
(G) High-resolution confocal image of a fibroblast from individual III-8 of family 1 illustrating the scattered Golgi structure. The scale bar
represents 10 mm.
(H and I) 3D reconstruction of a z stack of the Golgi from a control cell and from individual II-8 of family 2.
(J and K) Immunoblot analysis of cell lysates from individual 1:III-8 (J) or 2:II-6 and 2:II-8 (K) fibroblasts show a reduction of full-length
C11 in comparison to control cells. Different mobility of C11 results from different types of gel and buffer used for the experiments
shown in (J) and (K). Note the presence of possible C11 fragments in (K) suggesting a destabilization of the protein as a result of the
c.1287þ5G>A mutation.
(L) Lysates from fibroblasts from individuals II-6 and II-8 of family 2 (lanes 1–3) and control were prepared, and equal amounts (0.5 mg)
were incubated with anti-C11 IgG. The immune complexes were collected onto beads (lanes 4–6), eluted, and probed for the TRAPP
protein C2. Lanes 1–3 show equal amounts of C2 in the starting material. The C2 and C11 antibodies are noncommercial, generated
by the group of M.S. in rabbits against full-length His-tagged C2 and a peptide derived from the carboxy-terminal region of C11.
Antibodies were used as described.22cells and cells from affected individuals, displaying the
typical diffuse, reticular pattern (Figure 3A). Colocalization
of VSV-G with the Golgi marker manII is clearly seen after
30 minutes following release from the ER at 32C in both
control cells and cells from affected individuals
(Figure 3A). After 120 minutes, however, virtually all of
the VSV-G is found on the cell surface of control cells while
a significant amount of VSV-G remains in the Golgi of cells
from affected individuals (Figure 3A). Live-cell imaging
confirmed delayed VSV-G exit from the Golgi in cells
from affected individuals, pronounced from approxi-
mately 90 minutes, consistent with the findings of the
timed intervals above (Movie S1). The delay of VSV-G186 The American Journal of Human Genetics 93, 181–190, July 11, 2exit from the Golgi in cells from the affected individuals
suggests that generalized trafficking of molecules through
the Golgi might be delayed in these individuals as a result
of the in-frame deletion of TRAPPC11.
Delayed exit from the Golgi could arise from a defect in
anterograde traffic from the Golgi to the cell surface or
indirectly from defects in the endocytic pathway that
would fail to retrieve material from the Golgi needed for
anterograde traffic. To determine whether the trafficking
defect observed in cells from affected individuals was
due to defects in the endocytic pathway, we examined
the uptake of fluorescently tagged transferrin from the
cell medium but did not observe any uptake defects013
Figure 3. Altered VSV-G Trafficking and
LAMP1 Localization in Cells from Affected
Individuals
(A) Fibroblasts from a control and individ-
ual II:8 of family 2 were infected with virus
expressing VSV-G-ts045-GFP (VSV-G) for
1 hr and then incubated overnight at
37C. The cells were then shifted to 40C
for 6 hours at which point cyclohexamide
was added and the samples were trans-
ferred to 32C. Samples were removed at
0, 30, and 120 min following transfer to
32C and stained with the Golgi marker
mannosidase II (manII). The scale bar
represents 10 mm.
(B) Immunostaining with the late endo-
some/lysosome markers Rab9 and LAMP1
(Abcam, Cambridge, UK) demonstrated a
normal diffuse pattern of both proteins
in control fibroblasts but strong perinu-
clear localization in cells from affected
individuals. The scale bar represents
10 mm.
(C) Equal amounts of lysate prepared from
control, individual II:6 and individual II:8
of family 2 were probed for LAMP1,
LAMP2 (Abcam), and GAPDH as a loading
control.
(D) Equal amounts of cell lysate from fibro-
blasts of individual III:8 of family 1 and
control fibroblasts were incubated with
monoclonal antibodies against LAMP1,
LAMP2 (H4A3 and H4B4, respectively;
Santa Cruz Biotechnology, Santa Cruz,
USA), and b-actin as a loading control.(data not shown). However, immunostaining of cells
from affected individuals from family 2 for the late endo-
somal/lysosomal component lysosome-associated mem-
brane protein 1 (LAMP1) identified a striking difference
in the localization pattern compared to control cells
(Figure 3B). LAMP1 in control cells was seen in puncta
throughout the cell with the occasional deposition in
the perinuclear region (24% 5 1% of control cells [n ¼
189]), similar to other studies reporting LAMP1 localiza-
tion.28 Conversely, fibroblasts from affected individuals
displayed prominent perinuclear staining for LAMP1 in
a high proportion of cells (78% 5 2% and 87%53%
of cells in individual II-6 and individual II-8, respec-
tively [n ¼ 189 for all cases]). Immunostaining of
cells from affected individuals from family 2, as well as
immunoblotting of the corresponding cell lysates,
showed a reduced level of LAMP1 compared to control
(Figures 3B and 3C) and was concentrated in a higherThe American Journal of Humanmolecular-size region than in the
control, suggesting that it might be
more highly glycosylated. Levels
of lysosome associated membrane
protein 2 (LAMP2) did not appear
to be significantly reduced in cells
from affected individuals from family
2 but, like LAMP1, the proteinappeared to be more highly glycosylated (Figure 3C).
Moreover, immunoblot analysis of fibroblasts from indi-
vidual III-8 of family 1 also showed LAMP1 and LAMP2
alterations (Figure 3D).
Retention of the human growth-hormone marker pro-
tein GFP-FM4-hGH in the Golgi of HeLa cells following
knockdown of C11 was previously reported.25 In addition,
ablation of C11 by siRNAwas reported to result in accumu-
lation of VSV-G in a brefeldin A-resistant compartment,
interpreted to be related to the ERGIC (ER-Golgi intermedi-
ate compartment).22 Our finding that partial deletion of
the foie gras domain of C11 leads to defects in a post-Golgi
compartment might be explained by a milder functional
effect of the p.Ala372_Ser429del deletion compared to
knockdown of the entire protein. It is noteworthy that
several recent studies implicated the TRAPP complex in
retrograde traffic originating at the cell surface; however,
the precise location where TRAPP acts in this pathwayGenetics 93, 181–190, July 11, 2013 187
was not addressed.29,30 Our present study suggests that a
C11-containing TRAPP complex is involved in the forma-
tion and/or movement of late endosomes/lysosomes. A
prominent perinuclear staining of LAMP1 has been seen
in cells depleted of Rab9, leading to the suggestion that
effector molecules required for late endosomal transport
are not recruited in the absence of this GTPase.31 In addi-
tion, Rab7 and the lipid composition of membranes
has been implicated in the motility of late endosomes/
lysosomes.32 It will be of interest in the future to examine
the relationship between a C11-containing TRAPP com-
plex and various GTPases involved in late endosome
dynamics.
Mutations in TRAPPC2 and TRAPPC9, encoding TRAPP
complex components, cause X-linked spondyloepiphyseal
dysplasia tarda33 and postnatal microcephaly with ID,34,35
respectively. It has been suggested that the different effects
of mutations in TRAPPC2 and TRAPPC9 on human disease
are linked to the specific function and binding capacities of
each subunit.36 The similar Golgi phenotype observed in
fibroblasts from affected individuals from families 1 and
2 suggests similar functional effects of both TRAPPC11mu-
tations on TRAPP composition and function. Phenotypic
differences between our families could be explained by
different functional consequences of each alteration,
residing in different protein domains.
Our finding of LAMP1/LAMP2 alterations suggest a sim-
ilarity with the pathomechanism of Danon disease (MIM
300257), a myopathy caused by LAMP2 deficiency,37 char-
acterized by dilatative cardiomyopathy, proximal skeletal
muscle weakness, and ID.38 Danon disease is a rare
X-linked dominant disorder with early childhood onset
and an aggressive disease course in male affected individ-
uals, leading to death from cardiac complications in the
2nd to 3rd decade, if not prevented by heart transplanta-
tion. Female affected individuals show a milder disease
course, but many suffer from mild ID and muscle weak-
ness in addition to cardiac manifestations. Both sexes
might develop retinopathy, hepatic, and pulmonary dis-
ease.38,39 The molecular pathogenesis of Danon disease
exemplifies that defects in intracellular trafficking com-
ponents can cause a skeletal muscle phenotype with
associated ID.
In summary, we present a form of autosomal-recessive,
slowly progressive LGMD with childhood onset and high
CK, as well as a syndrome consisting of myopathy, ID,
hyperkinetic movements, and ataxia, caused by homozy-
gous mutations in the membrane trafficking component
TRAPPC11. Thus, the presence of myopathy and high CK
with or without additional symptoms in a person should
alert clinicians for TRAPPC11 deficiency. Both mutations
lead to a range of molecular defects including altered
TRAPP complex composition, impaired Golgi morphology,
and altered protein transport along the secretory pathway.
These results suggest that altered membrane trafficking
is the underlying molecular mechanism of this disease
spectrum.188 The American Journal of Human Genetics 93, 181–190, July 11, 2Supplemental Data
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